Evaluation of Immuno-Modulatory Potential of Ayurvedic Medicines in Patients with Mild Symptoms of COVID-19: Single Blinded, Randomized and Controlled Study - NI

Shree Baidyanath Ayurved Bhawan Pvt Ltd0 个研究点目标入组 92 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Age more than 18 or less than 75 years at time of signing Informed Consent Form.
•COVID positive by RTPCR
•Cases that have been assigned as mild or very mild or asymptomatic cases of COVID.
•Cases presenting with fever and/or upper respiratory tract illness (Influenza like illness, ILI).
•No difficulty in swallowing oral medications.
•Must agree not to enroll in another study of an investigational agent prior to completion of study.

•Allergies, known to be allergic to research drugs or drug excipients;
•Subject weight is less than 40 kg
•Pneumonia with/without signs of severe disease.
•COVID Cases with ARDS or Septic shock.
•Patients who have participated in other clinical trials within 1 month.
•Known patients with impaired renal function (estimated creatinine clearance <60 mL / min
•During the screening or within 24 hours before screening, patients were found to have any of the following laboratory parameter abnormalities (based on local laboratory reference range):-ALT or AST level 5 times the upper limit of normal range (ULN) or-ALT or AST more than 3 times ULN and total bilirubin levels more than 2 times ULN.
•Being pregnant or breastfeeding, or having a positive pregnancy test at the time of pre-dose inspection, or planning to become pregnant within 3 months of study treatment.

发起方

Shree Baidyanath Ayurved Bhawan Pvt Ltd